Cancer Drug Resistance
All Journals
Search Log In
Home Articles Special Issues Volumes Webinars Videos
Cancer Drug Resistance
Search Submit
Home Articles Special Issues Volumes Webinars Videos

fig7

From:  Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors
Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Figure 7. Measurement of PD-L1 gene expressions in NSCLC patients during treatments with immunotherapy agents. Chemotherapy includes carbo-pemetrexed; targeted therapy includes erlotinib, osimertinib, and crizotinib. NSCLC: Non-small cell lung cancer.

Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
© 2016-2025 OAE Publishing Inc., except certain content provided by third parties